The SPRAY-CB trial marks the first pivotal study of a medical device therapy targeting the underlying cause of Chronic Bronchitis. Boston,MA. – October 22, 2020: CSA Medical Inc., a developer of medical devices advancing the power of liquid nitrogen spray cryotherapy,...
Published by Mass Device Medical Network CSA Medical announced this week that it won CE Mark approval for its RejuvenAir system for treating chronic obstructive pulmonary disease (COPD) with chronic bronchitis (CB). The RejuvenAir system that is designed to apply...
Published by RT Magazine Health officials in Europe OK’d CSA Medical’s cryotherapy system to treat chronic obstructive pulmonary disease (COPD) with chronic bronchitis. The system applies metered sprayed liquid nitrogen at -196 C to areas within the lungs through a...
BOSTON, Oct. 3, 2019 /PRNewswire CSA Medical, Inc., presented positive 12-month results of its feasibility study for the RejuvenAir Metered Cryospray™ system yesterday at the 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain. In the...
Published by MassDevice Medical Network CSA Medical said today that results of its feasibility study into the RejuvenAir metered cryospray system showed improved quality of life in patients who have chronic obstructive pulmonary disease with chronic bronchitis. The...
CAUTION: When reading this news item please be aware that the RejuvenAir System is an Investigational device, limited by United States Federal law to investigational use only. Not for Sale in the United States of America.